Crown Bioscience, a global contract research organization (CRO), and JSR Lifesciences announced the launch of a groundbreaking service, OrganoidXplore. Announced. This large-scale organoid panel screening platform delivers robust, highly reproducible, and clinically relevant results in record time to accelerate preclinical cancer therapy drug discovery and cancer therapy development. gives researchers the power to reshape the landscape.
Screening of large panels of patient-derived organoids is made possible using Crown Bioscience’s proprietary assay-ready (AR) organoid technology. Recent posters presented at the AACR Annual Meeting and ANE International Conference 2023 demonstrate the performance of assay-ready organoids versus freshly prepared organoids using traditional methodologies. This study demonstrated the usefulness of OrganoidXplore and revealed the following:
– Robust and highly reproducible : Both the assay-ready method and the original method demonstrated consistently high precision across multiple assays.
– Shorter timelines and lower costs : OrganoidXplore reduced project schedules by two-thirds compared to standard methods.
Comparison of reliable and reproducible drug responses : both methods showed similar results in cell viability (CTG) and high content imaging (HCI) assays when tested with standard drugs such as paclitaxel, carboplatin, and cisplatin I showed you the results.
OrganoidXplore transcends the limitations of traditional 2D cell culture systems in terms of patient relevance and heralds a major leap forward in preclinical drug screening. By accurately replicating the genomic, morphological, and pathophysiological characteristics of the original tumor, researchers can now screen against a wide range of predictive models. Results are obtained in as little as 6 weeks, increasing research speed by 3x and delivering the robustness and reproducibility of advanced assay-ready technology.
Researchers can choose between a comprehensive Full Panel or a KRAS Panel focused on specific goals. The Full Panel currently consists of 50 organoid models covering seven cancer indications, which are also available as companion PDXs (patient-derived xenografts). The KRAS Panel specifically targets four cancer indications and covers a wide range of KRAS mutations in 25 models. These models are also available as PDX, allowing seamless transition to subsequent exams.
Combined with comprehensive next-generation sequencing (NGS) features including whole exome sequencing (WES) and RNA sequencing (RNAseq), OrganoidXplore enables rapid biomarker identification, relevant mode-of-action studies, and Enables selection of indications and models, consideration of drug repurposing, and improved patient stratification.
Dr. Leo Price , Senior Vice President In Vitro and Head of Crown Bioscience Netherlands said: “OrganoidXplore meets the demanding demands of pioneering research initiatives by offering a diverse selection of models covering a wide range of genetic backgrounds and mutations. Thanks to innovative organoid cryopreservation technology automation and assay automation, , OrganoidXplore’s accuracy, speed, and reproducibility are second to none.”
Crown Bioscience remains steadfast in its commitment to driving innovation in oncology research, as demonstrated by the introduction of OrganoidXplore, designed with a mission to accelerate drug discovery.
SOURCE: Businesswire